DBV Technologies (EPA:DBV), (NASDAQ:DBVT) is a biopharmaceutical company focused on developing and commercializing treatments for food allergies, particularly peanut allergies in children, through its innovative Viaskin technology. This epicutaneous immunotherapy (EPIT) platform leverages a patch-based approach aiming to provide a non-invasive treatment option for patients. DBV Technologies is committed to improving the lives of those suffering from food allergies by advancing research and striving towards the commercial availability of their treatments. Operating with a strong commitment to safety, efficacy, and patient accessibility, their primary objective is to bring transformative therapies to the market, addressing a significant unmet need within the allergy therapeutic space.